Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Mergers & Acquisitions
Boston Scientific acquires EndoTex Interventional Systems
January 29th, 2007
Boston Scientific Corp. (BSX) announced it has acquired EndoTex Interventional Systems, Inc. The acquisition follows the Food and Drug Administration (FDA) approval of the NexStent Carotid Stent System, which was studied in the CABERNET trial along with the Boston Scientific FilterWire EZ Embolic Protection System. Terms of the acquisition were not disclosed. "Combining the resources of these two organizations demonstrates Boston Scientific's commitment to leadership in treating carotid artery disease," said John Pedersen, president of Boston Scientific's Peripheral Interventions business. "Incorporating the NexStent Carotid Stent into our portfolio...
Source: Biotech Business Week (2007-01-29)
|
